ClinConnect ClinConnect Logo
Search / Trial NCT01176045

TearLab Refractive Surgery Dry Eye Study

Launched by TEARLAB CORPORATION · Aug 3, 2010

Trial Information

Current as of July 25, 2025

Completed

Keywords

Dry Eye Disease Osmolarity Refractive Surgery Lasik Tear Lab

ClinConnect Summary

Dry eye disease is a common and major source of disability, whether occurring as a primary disorder or as a component of other diseases and its onset may be triggered or modified by exposure to systemic drugs, contact lens wear, ocular surgery and adverse environmental and work conditions. The development of a reliable, highly sensitive and specific test for the clinical diagnosis of dry eye is a major unmet clinical need, particularly to differentiate it from common conditions such as ocular allergy which exhibit similar presenting symptoms. Tear hyper-osmolarity is central to the dry eye ...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Male or female, twenty-one years of age or older.
  • Confirmed diagnosis of refractive error receiving LASIK surgery.
  • Patient motivation and willingness to cooperate with the investigator and ability to return for all visits during the study.
  • Exclusion Criteria:
  • Compromised cognitive ability that may be expected to interfere with study compliance.
  • Clinically significant eyelid deformity or eyelid movement disorder that is caused by conditions such as notch deformity, incomplete lid closure, entropion, ectropion, hordeola or chalazia.
  • Previous ocular disease leaving sequelae or requiring current topical eye therapy other than for DED, including, but not limited to: active corneal or conjunctival infection of the eye and ocular surface scarring.
  • Active ocular allergy
  • Patients requiring punctual occlusion prior to surgery
  • Patients requiring cyclosporine ophthalmic emulsion prior to surgery
  • Standard exclusion criteria for refractive surgery used by each surgeon.
  • Known hypersensitivity to any of the agents used in testing
  • Ophthalmologic drop use within 2 hours of any visit

About Tearlab Corporation

TearLab Corporation is a pioneering medical technology company dedicated to advancing the diagnosis and management of ocular surface diseases, particularly dry eye syndrome. Leveraging its innovative TearLab Osmolarity System, the company focuses on developing precise, point-of-care diagnostic solutions that enhance clinical decision-making and improve patient outcomes. With a commitment to research and development, TearLab Corporation collaborates with healthcare professionals to explore new therapeutic avenues and ensure the highest standards of patient care in ophthalmology.

Locations

Fairfield, Connecticut, United States

Westchester, Illinois, United States

Oklahoma City, Oklahoma, United States

Tulsa, Oklahoma, United States

King Of Prussia, Pennsylvania, United States

San Antonio, Texas, United States

Salt Lake City, Utah, United States

Reston, Virginia, United States

Patients applied

0 patients applied

Trial Officials

James Owen, OD

Study Director

TLC The Laser Eye Center

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials